News Sentiment

GLSI sentiment intelligence

Greenwich Lifesciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.80 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-10.0% over one week, -17.7% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Greenwich LifeSciences Says EU Regulator Approves Combination of HLA Patients in Phase 3 Trial

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -10.0% Price reacting lower
Trend fit Trend inactive -17.7% over four weeks
Fair value 39.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 31
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
TradingKey 6
TradingView 5
Stock Titan 4
GlobeNewswire 4
Stock Traders Daily 3
Finviz 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 14
Regulatory and legal 8
Guidance 2
Analyst action 1
Balance sheet 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-54 of 54
TradingKey Direct company coverage

Greenwich Lifesciences Inc (GLSI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Greenwich Lifesciences Inc (GLSI), outlining both major individual and institutional holdings. It provides a breakdown of shareholder types, including individual investors, investment advisors, and hedge funds, along with a histor

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 17:40
Source
TradingKey
Intellectia AI Direct company coverage

GLSI Stock News Today | Earnings, Events & Price Alerts

Greenwich LifeSciences (GLSI) has provided updates on its clinical trials and financial reporting. The company presented positive Phase 3 data for its breast cancer vaccine at the ASCO Annual Meeting, showing a significant increase in immune responses. GLSI also addressed delays

Tone
Positive 65/100
Event
Earnings
Published
16 Jun 2026 19:09
Source
Intellectia AI
Stock Traders Daily Direct company coverage

Technical Reactions to GLSI Trends in Macro Strategies

This article provides a technical analysis of Greenwich Lifesciences Inc. (NASDAQ: GLSI), highlighting a positive near-term sentiment within a long-term strong context. It details institutional trading strategies, including position trading, momentum breakout, and risk hedging, b

Tone
Positive 72/100
Event
Market update
Published
15 Jun 2026 15:54
Source
Stock Traders Daily
GlobeNewswire Direct company coverage

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

Greenwich LifeSciences, Inc. presented open-label data from its FLAMINGO-01 Phase III trial at the ASCO Annual Meeting 2026, showcasing statistically significant increased injection site reaction (ISR) immune responses in non-HLA-A*02 breast cancer patients treated with GLSI-100.

Tone
Positive 70/100
Event
Market update
Published
06 Jun 2026 14:44
Source
GlobeNewswire
Minichart Direct company coverage

Greenwich LifeSciences, Inc. Q1 2026 Quarterly Report: Financials, Risk Factors, and Disclosure Highlights

Greenwich LifeSciences (GLSI) released its Q1 2026 unaudited financial statements, showing a sharp increase in net loss to $5.6 million due to higher clinical trial expenses. The company successfully raised capital through ATM offerings, but also disclosed material weaknesses in

Tone
Negative 37/100
Event
Market update
Published
05 Jun 2026 00:36
Source
Minichart